Kessler RC, McGonagle KA, Zhao S, et al. - Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry, 1994, 51, 8-19.
Pitchot W, Constant E. - Troubles dépressifs unipolaires. In Dierick M, Claes S, De Nayer A, Cosyns P, Constant E, Souery D (Eds), Man Psychopharmacol Gent, Academia Press, 2012.
Rush AJ, Trivedi MH, Wisniewski SR, et al. - Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med, 2006, 354, 1231-1242.
Blier P, Blondeau C. - Neurobiological basis and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. J Affect Disord, 2011, 128, 3-10.
Pitchot W, Scantamburlo G, Ansseau M. - Dopamine and depression: the forgotten neurotransmitter. Rev Méd Liège, 2008, 63, 378-384.
Berman RM, Fava M, Thase ME, et al. - Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to anti depressants. CNS Spectr, 2009, 14, 197-206.
Nelson JC, Thase ME, Trivedi MH, et al. - Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry, 2009, 11, 344-352.
Nelson JC, Mankoski R, Baker RA, et al. - Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a posthoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord, 2010, 120, 133-140.
Citrome L. - Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med, 2010, 122, 39-48.
Trivedi MH, Thase ME, Fava M, et al. - Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry, 2008, 69, 1928-1936.
Trivedi MH, Thase ME, Osimtokim O, et al. - An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry, 2009, 70, 387-396.
Tohen M, Case M, Trivedi MH, et al. - Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry, 2010, 71, 451-462.
MeElroy SI, Guerdjikova A, Mori N, et al. - Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Oiíri Investis Druss, 2010, 19, 1527-1544.
Nelson JC, Papakostas GI. - Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry, 2009, 166, 980-991.
Keitner GI, Garlow SJ, Ryan CE, et al. - A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res, 2009, 43, 205-214.
Alexopoulos GS, Canuso CM, Gharabawi GM, et al. - Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry, 2008, 16, 21-30.
Souery D, Pitchot W. - Traitement de la dépression bipolaire et rôle des antidépresseurs. Phramacothérapie des troubles bipolaires, in Ferrero F, Aubry JM, Schaad N, 2013.
De Fruyt J, Deschepper E, Audenaert K, et al. - Second generation antipsychotic s in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol, 2012, 26, 603-617.